Tripletâs New Huntington Disease Drug May Also Treat Other Repeat Expansion Disorders
Source: Pixabay
April 28, 2021
In a virtual presentation at the CHDI Foundationâs 16
th Annual Huntingtonâs Disease (HD) Therapeutics Conference, Triplet Therapeutics presented preclinical data on the therapeutic target and route of administration of its first clinical candidate, an antisense oligonucleotide, TTX-3360. This is the first therapeutic candidate with the potential to modify the course of HD and other repeat expansion disorders (REDs).
Triplet Therapeutics also pledged to place 1% of its equity into an independently managed trust fund that will monetize the equity to benefit RED patients and their families. âI think this is really important. Itâs the first time this has ever been done in the biotech industry. I hope the industry looks at this and uses it as a template across other indications,â said Nessan Bermingham, PhD, Triplet Therapeutics CEO, pre